A Study to Evaluate Positive SARS-CoV-2 Antibodies in Subjects with Bipolar Disorder

Overview

About this study

The purpose of this study is to evaluate the clinical and neurocognitive correlates of COVID-19 in patients with bipolar disorder (BD). 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age, 18-65 years.
  • Diagnosis of BD-I or BD-II, or SCZ-BD by DSM-IV (SCID confirmed). Participants of the Bipolar Biobank (IRB # 08-008794) are patients with existing SCID results and participants enrolling to the MoStGEN protocol (IRB # 20-001658) are required to complete a SCID; thus they will not be required to repeat the SCID assessment. Only patients without a previous SCID will be interviewed to complete it.
  • Subjects willing to provide consent to be blood-tested for SARS-CoV-2 IgG/IgM on each of the three visits.

Exclusion Criteria:

  • Inability to understand English.
  • Inability or unwillingness to provide informed consent or scoring less than 80% on the comprehension assessment (CA) form.
  • Unwilling to consent to providing bio-specimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design.
  • Actively psychotic (i.e., paranoia, perceptual disturbances, delusional ideas, impaired judgment) or active suicidal behavior (including suicidal ideation or planning).
  • Involuntary patients.
  • Women with known pregnancy. (Due to the lack of conclusive data regarding the quality of antibody response during pregnancy, we considered it appropriate the exclusion of women with known pregnancy from this study).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Open for enrollment

Contact information:

Laura Harper B.S.

(507) 255-9352

Harper.Laura1@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20510982

Mayo Clinic Footer